Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2022-08-03 Sale | 2022-08-04 4:32 pm | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 5,959 | $73.73 | $439,328 | 28,672 (Direct) | View |
| 2022-08-02 Sale | 2022-08-03 4:44 pm | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 837 | $69.66 | $58,305 | 551,176 (Direct) | View |
| 2022-08-02 Sale | 2022-08-03 4:44 pm | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 437 | $69.66 | $30,441 | 34,631 (Direct) | View |
| 2022-08-02 Sale | 2022-08-03 4:44 pm | NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer | 414 | $69.66 | $28,839 | 102,193 (Direct) | View |
| 2022-06-10 Sale | 2022-06-16 4:22 pm | NovoCure Ltd | NVCR | HILLEMAN JERYL L Director | 407 | $69.61 | $28,331 | 2,537 (Direct) | View |
| 2022-05-10 Sale | 2022-05-12 4:30 pm | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 4,205 | $63.17 | $265,646 | 34,846 (Direct) | View |
| 2021-07-31 Sale | 2022-03-11 4:54 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 3,669 | $71.19 | $261,196 | 86,904 (Direct) | View |
| 2022-03-07 Sale | 2022-03-09 4:56 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 7,775 | $69.73 | $542,116 | 81,908 (Direct) | View |
| 2022-03-08 Sale | 2022-03-09 4:55 pm | NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer | 744 | $70.1 | $52,154 | 102,295 (Direct) | View |
| 2022-03-08 Sale | 2022-03-09 4:53 pm | NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer | 1,037 | $70.1 | $72,694 | 55,991 (Direct) | View |
| 2022-03-08 Sale | 2022-03-09 4:52 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer | 2,923 | $70.1 | $204,902 | 165,102 (Direct) | View |
| 2022-03-08 Sale | 2022-03-09 4:51 pm | NovoCure Ltd | NVCR | Cordova Ashley CFO | 759 | $70.1 | $53,206 | 60,848 (Direct) | View |
| 2022-03-08 Sale | 2022-03-09 4:50 pm | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 2,339 | $70.1 | $163,964 | 62,462 (Direct) | View |
| 2022-03-08 Sale | 2022-03-09 4:48 pm | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 2,385 | $70.1 | $167,189 | 552,013 (Direct) | View |
| 2022-03-03 Sale | 2022-03-07 6:28 pm | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 3,067 | $71.87 | $220,414 | 70,907 (Direct) | View |
| 2022-03-03 Sale | 2022-03-07 6:26 pm | NovoCure Ltd | NVCR | Cordova Ashley CFO | 1,705 | $73.16 | $124,744 | 104,411 (Direct) | View |
| 2022-03-03 Sale | 2022-03-07 6:23 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 5,543 | $72.54 | $402,064 | 133,941 (Direct) | View |
| 2022-03-03 Sale | 2022-03-07 6:18 pm | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 2,313 | $71.83 | $166,136 | 79,131 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2022-08-02 Option Award | 2022-08-03 4:45 pm | N/A N/A | NovoCure Ltd | NVCR | Cordova Ashley CFO | 7,122 | $70.2 | 73,261 (Direct) | View |
| 2022-07-05 Option Award | 2022-07-07 5:51 pm | N/A N/A | NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer | 281 | $59.08 | 49,483 (Direct) | View |
| 2022-07-05 Option Award | 2022-07-07 5:50 pm | N/A N/A | NovoCure Ltd | NVCR | Ben Arye Barak General Counsel | 144 | $59.08 | 17,002 (Direct) | View |
| 2022-07-05 Option Award | 2022-07-07 5:49 pm | N/A N/A | NovoCure Ltd | NVCR | Cordova Ashley CFO | 251 | $59.08 | 66,139 (Direct) | View |
| 2022-07-05 Option Award | 2022-07-07 5:48 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer | 218 | $59.08 | 165,320 (Direct) | View |
| 2022-07-05 Option Award | 2022-07-07 5:48 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 276 | $59.08 | 13,583 (Direct) | View |
| 2022-07-05 Option Award | 2022-07-07 5:47 pm | N/A N/A | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 222 | $59.08 | 35,068 (Direct) | View |
| 2022-07-05 Option Award | 2022-07-07 5:46 pm | N/A N/A | NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer | 312 | $59.08 | 102,607 (Direct) | View |
| 2022-07-05 Option Award | 2022-07-07 5:45 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 312 | $59.08 | 83,499 (Direct) | View |
| 2022-07-05 Option Award | 2022-07-07 5:44 pm | N/A N/A | NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer | 213 | $59.08 | 56,204 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-10 4:12 pm | N/A 2032-06-08 | NovoCure Ltd | NVCR | Madden Martin J. Director | 8,700 | $0 | 8,700 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-10 4:11 pm | N/A 2032-06-08 | NovoCure Ltd | NVCR | Hung David Director | 6,777 | $0 | 13,491 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-10 4:10 pm | N/A 2032-06-08 | NovoCure Ltd | NVCR | Scannell Timothy J Director | 8,700 | $0 | 8,700 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-10 4:10 pm | N/A 2032-06-08 | NovoCure Ltd | NVCR | VERNON W ANTHONY Director | 8,700 | $0 | 8,700 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-10 4:09 pm | N/A 2032-06-08 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 6,777 | $0 | 79,636 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-10 4:08 pm | N/A 2032-06-08 | NovoCure Ltd | NVCR | HILLEMAN JERYL L Director | 8,700 | $0 | 8,700 (Direct) | View |
| 2022-05-05 Gift | 2022-05-09 4:14 pm | N/A 2026-01-12 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer | 2,648 | $0 | 147,048 (Indirect) | View |
| 2022-04-14 Ownership | 2022-04-14 4:36 pm | N/A N/A | NovoCure Ltd | NVCR | Ben Arye Barak General Counsel | 0 | $0 | 50,806 (Direct) | View |
| 2022-03-03 Exercise | 2022-03-11 4:55 pm | N/A 2025-04-22 | NovoCure Ltd | NVCR | Cordova Ashley CFO | 3,840 | $15.6 | 73,624 (Direct) | View |
| 2022-03-03 Exercise | 2022-03-11 4:55 pm | N/A 2026-02-24 | NovoCure Ltd | NVCR | Cordova Ashley CFO | 1,200 | $11.46 | 73,624 (Direct) | View |
| 2021-07-31 Exercise | 2022-03-11 4:54 pm | 2021-07-31 N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 3,717 | $0 | 86,904 (Direct) | View |
| 2021-07-31 Exercise | 2022-03-11 4:54 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 3,717 | $154.01 | 86,904 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:28 pm | 2023-03-01 2032-02-29 | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 6,106 | $80.59 | 70,907 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:26 pm | 2023-03-01 2032-02-29 | NovoCure Ltd | NVCR | Cordova Ashley CFO | 42,804 | $80.59 | 104,411 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:26 pm | N/A N/A | NovoCure Ltd | NVCR | Cordova Ashley CFO | 21,508 | $0 | 104,411 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:25 pm | 2023-03-01 2032-02-29 | NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer | 35,383 | $80.59 | 84,569 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:25 pm | N/A N/A | NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer | 17,371 | $0 | 84,569 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:23 pm | 2023-03-01 2032-02-29 | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 44,258 | $80.59 | 133,941 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:23 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 21,714 | $0 | 133,941 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:22 pm | 2023-03-01 2032-02-29 | NovoCure Ltd | NVCR | Danziger Asaf CEO | 13,470 | $80.59 | 13,470 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:21 pm | 2023-03-01 2032-02-29 | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 14,581 | $80.59 | 14,581 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:18 pm | 2023-03-01 2032-02-29 | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 35,874 | $80.59 | 79,131 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 6:18 pm | N/A N/A | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 17,371 | $0 | 79,131 (Direct) | View |